

In the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-5. (Canceled).

6. (Currently Amended) A method of inducing an immunoresponse to CASB7439 ASCL2 in a human or non-human animal comprising administering a peptide fragment of SEQ ID NO:2 to the human or non-human animal, said peptide fragment comprising an epitope of SEQ ID NO:2.

7. (Original) The method of claim 6, wherein the peptide fragment is selected from the group consisting of SEQ ID NO: 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, and 33.

8. (Original) The method of claim 6, wherein the peptide fragment further comprises a fusion partner.

9. (Original) The method of claim 6 or 8, further comprising admixing the peptide fragment with an adjuvant.

10-22. (Canceled).